DexCom (XSWX:DXCM) EBITDA per Share: CHF2.94 (TTM As of Mar. 2026)


XSWX:DXCM DexCom Inc XSWX:DXCM
90 GF Score
Price CHF56.54
GF Value CHF85.31
! 3 Warning Signs
View Full Analysis

What is DexCom EBITDA per Share?

DexCom XSWX:DXCM 90 EBITDA per Share is CHF2.94 as of Mar. 2026. GuruFocus rates XSWX:DXCM with a GF Score™ of 90/100 and a GF Value™ of CHF85.31. The stock has 3 warning signs investors should review. Among 698 Medical Devices & Instruments companies, DexCom ranks better than 81.38% on this metric.

DexCom's EBITDA per Share for the three months ended in Mar. 2026 was CHF0.68. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF2.94.

During the past 12 months, the average EBITDA per Share Growth Rate of DexCom was 54.80% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 36.30% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 31.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for DexCom's EBITDA per Share or its related term are showing as below:

XSWX:DXCM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -24.9   Med: 17.95   Max: 37.5
Current: 36.3

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of DexCom was 37.50% per year. The lowest was -24.90% per year. And the median was 17.95% per year.

XSWX:DXCM's 3-Year EBITDA Growth Rate is ranked better than
81.38% of 698 companies
in the Medical Devices & Instruments industry
Industry Median: 7.95 vs XSWX:DXCM: 36.30

DexCom's EBITDA for the three months ended in Mar. 2026 was CHF267 Mil.

During the past 12 months, the average EBITDA Growth Rate of DexCom was 51.70% per year. During the past 3 years, the average EBITDA Growth Rate was 33.90% per year. During the past 5 years, the average EBITDA Growth Rate was 31.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of DexCom was 38.40% per year. The lowest was -70.70% per year. And the median was -5.10% per year.


DexCom  (XSWX:DXCM) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


DexCom EBITDA per Share Related Terms


DexCom EBITDA per Share Historical Data

* Premium members only.

The historical data trend for DexCom's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexCom EBITDA per Share Chart

DexCom Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.81 1.23 1.86 2.04 2.67

DexCom Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.62 0.82 0.82 0.68
XSWX:DXCM
90GF Score
DexCom Inc XSWX:DXCM
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexCom EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

DexCom's EBITDA per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA per Share(A: Dec. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=1082.589/405.500
=2.67

DexCom's EBITDA per Share for the quarter that ended in Mar. 2026 is calculated as

EBITDA per Share(Q: Mar. 2026 )
=EBITDA/Shares Outstanding (Diluted Average)
=267.446/393.600
=0.68

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF2.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of CHF2.94 mean?
DexCom (XSWX:DXCM) has a EBITDA per Share of CHF2.94 as of Mar. 2026. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on DexCom and its competitors. According to the industry distribution chart, DexCom ranks #130 out of 698 companies in the Medical Devices & Instruments industry, placing it in the top 18.6%.
Is DexCom's EBITDA per Share too high?
DexCom's current EBITDA per Share is CHF2.94. Based on the distribution chart, DexCom ranks #130 out of 698 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, DexCom has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does DexCom's EBITDA per Share compare to GEHC and STE?
According to the Medical Devices & Instruments industry distribution chart, DexCom ranks #130 out of 698 companies for EBITDA per Share. This places DexCom in the top 19% of its industry — outperforming the majority of peers. The industry median EBITDA per Share is 7.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Medical Devices & Instruments company?
The median EBITDA per Share among Medical Devices & Instruments companies is 7.95, based on 698 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on DexCom and its competitors. For the Medical Devices & Instruments industry, the median EBITDA per Share is 7.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DexCom's current EBITDA per Share is CHF2.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
DexCom (XSWX:DXCM) has a current EBITDA per Share of CHF2.94. The stock's GF Value™ is CHF85.31, compared to a current price of CHF56.54 — trading 33.7% below its estimated fair value. The current EBITDA per Share is CHF2.94. DexCom's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For DexCom (XSWX:DXCM), the current EBITDA per Share is CHF2.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DexCom (XSWX:DXCM) Overvalued in 2026?

Based on GuruFocus' analysis, DexCom stock appears to be undervalued. The current stock price of CHF56.54 is trading 33.7% below its estimated GF Value™ of CHF85.31.

Key valuation signals for XSWX:DXCM:

  • EBITDA per Share: CHF2.94
  • GF Value™: CHF85.31 vs. price of CHF56.54 (33.7% below fair value)
  • GF Score™: 90/100 with 3 warning signs

No single metric tells the full story. See the XSWX:DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


DexCom Business Description

Address 6340 Sequence Drive, San Diego, CA, USA, 92121
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
90GF Score

Get the complete analysis for XSWX:DXCM

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF56.54
Price
CHF85.31
GF Value